Compositions comprising GSK-3 and / or beta-catenin inhibitors and / or degraders and methods of use thereof
Alectinib and Gilteritinib, combined with compounds of Formula (I) or Niclosamide, provide a synergistic approach to inhibit GSK-3 and β-catenin, addressing the inadequacies of current treatments and effectively treating diseases by modulating these proteins and reducing viral replication.
Patent Information
- Application Number
- PCT/US2025/030118
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-12-03
- Filing Date
- 2025-05-20
- Publication Date
- 2025-11-27
AI Technical Summary
Current treatments for diseases associated with overactive or dysregulated Glycogen Synthase Kinase 3 (GSK-3) and β-catenin are inadequate, and there is a need for effective compositions that can inhibit these proteins to treat conditions such as cancer, COVID-19, bipolar disorder, Alzheimer's disease, metabolic disorders, and chronic inflammatory diseases.
The use of Alectinib and Gilteritinib, in combination with compounds of Formula (I) or Niclosamide, to inhibit GSK-3 and/or β-catenin, administered therapeutically to modulate their activity and treat associated diseases.
The combination of these compounds synergistically reduces hyperphosphorylation of the coronavirus nucleocapsid protein, inhibits viral replication, and effectively treats conditions by targeting GSK-3 and β-catenin pathways, offering therapeutic benefits for various diseases.